HEALTH
SOLUTION FOR ALL NEED
Turnkey Project for Biosimilar Manufacturing
Formulation development
Robust Formulations for Therapeutic and Commercial Success
From the early stages of research and development, a robust formulation is crucial for paving the road to a successful commercialization because biopharmaceutical molecules are often inherently unstable and require stabilization. Our formulation development services deliver biopharmaceutical drug products that are robust for manufacturing, storage, handling, and administration to patients. We offer formulation development for wide range of structurally diverse (bio)pharmaceuticals, including proteins, vaccines, gene therapy products, viral vectors, nucleic acids, antibodies or related products, peptide, cell therapy products, drug delivery system and small molecules.
Liquid, frozen and lyophilized formulations tailored to your needs
We develop formulations for liquid, frozen and lyophilized drug products that fit the needs of your molecule and development phase. In a unique collaborative approach, our experts concentrate on your target product profile (TPP) and tailor the study design to your requirements. We consider drug substance availability, relevant deadlines and your overall development strategy when conducting a project. Already during initial project discussions with us, you will benefit from the advice of our distinguished scientific advisory board. Also, our large service portfolio gives you the flexibility to readily switch from a liquid to a lyophilized formulation or explore different formulation types in parallel.
With many years of experience in the field of formulation development, we offer:
● preformulation screening: including identifying suitable formulation corridor and composition (pH, ionic strength, protein concentration, excipients, etc.); identifying degradation products; selecting stability-indicating methods; high throughput formulation approaches based on design of experiment are possible to reduce the required material and time
● preclinical formulation development: liquid, frozen or freeze-dried formulations (e.g., for toxicological studies) are developed and can be produced under aseptic conditions
● transfer of formulations to the external CMO of your choice including process transfer on site if desired. This reduces your costs and maintains your flexibility
● formulation development for clinical phase I and II
● formulations for late clinical development (phase III) and commercial application
Do you have any questions?
Our experts are happy to discuss your questions and inquiries related to formulation development!
Get a tailored formulation development for your product
Our formulation development will be tailored to your specific drug substance, development phase and target product profile (TPP), and is backed by many years of experience with similar drug substances. Click on a product type to explore our entire portfolio of specialized development and analytical services.
DoLet's talk!
Find out how you can benefit from a tailored and science-driven formulation development.
-
-
Pekin Pharma is formulating innovation
We follow our strategy of “formulating innovation” by combining technologies, knowledge, and experience. A unique mix, which supports formulation patent application and patent life cycle management in later phases. “Formulating innovation” adds substantial financial value to your drug discovery pipeline: with a tailor-made development strategy, we reduce your time-to-market and increase the value of your drug development project for out-licensing and M&A activities. Pekin Pharma will seek no financial participation in generated IP – no royalties, no milestone payments.
-
A successful formulation development needs suitable analytical methods
A formulation development can only be conducted successfully when it is based on product-specific, selective and sensitive stability-indicating analytical methods. If the employed analytics cannot detect critical degradation pathways, all formulations will appear stable, and no selection is possible. The choice of the most suitable analytical methods is based on the knowledge of the degradation pathways and the understanding of their criticality.
Pekin Pharma will include a tailored and orthogonal analytical package to get a maximum insight into the stability of your drug substance and its degradation pathways. Our expert scientists are skilled in setting up dedicated analytical methods that suits your product characteristics.
-
Quality & biosafety level of this service
We provide all our services with the highest quality standards. Each project is carried out by experienced scientists and every report or data presentation is comprehensively checked by a scientific reviewer. We offer this service with the following quality and biosafety level:
Our know-how related to formulation development
Pekin Pharma is a science-driven service provider. We perform internal research projects with academic and industrial partners to develop new technologies and create in-depth knowledge, which directly benefits our client projects. Our internal Unit Science & Technology, hosting PhD candidates and Postdocs, also actively contributes to the scientific community with numerous peer-reviewed publications each year. Explore our latest publications, articles, and webinars.
-
Medical Intermediates and API
Nivelles, Belgium – Thursday, March 7, 2024 - Quantoom Biosciences S.A. (“Quantoom”), part of PEKIN PHARMA S.A. is proud to announce its significant collaboration with the Institute of Technology on Immunobiologicals (Bio-Manguinhos/Fiocruz)2024-06-03
more
-
Press Release :PEKIN PHARMA has signed a Memorandum of Understanding with the Indonesian government to focus on building a thriving biopharmaceutical ecosystem in Indonesia
PEKIN PHARMA was honored to host leaders from Indonesia's Ministry of Health and Social Welfare, who are leading the Presidential Initiative to Unlock the Healthcare Value Chain (PVAC). The event was hosted by Mohamed, CEO of PEKIN PHARMA, and PEKIN PHARMA is pleased to announce a new partnership with the Indonesian government.2024-06-03
more
-
Introduction to Alemtuzumab
Alemtuzumab, also known as Lemtrada, is a humanized monoclonal antibody targeting CD52 that is primarily used in the treatment of multiple sclerosis (MS) and chronic lymphocytic leukemia (B-CLL). Its mechanism of action is to kill tumor cells through complement dependent cytotoxicity (CDC) and antibody dependent cytotoxicity (ADCC).2024-06-03
more
-
Health Innovation & the Future of Medicines Development
The future of health innovation and pharmaceutical development will be an era of diversity, technology-driven and interdisciplinary integration. And gene and cell therapy is becoming a new research hotspot. These emerging technologies can not only provide more accurate treatment options, but also effectively overcome the limitations of traditional drugs, such as resistance and off-target effects.2024-06-03
more
-
PEKIN PHARMA Sells a Wide Range of Premium Monoclonal Antibodies
PEKIN PHARMA is involved in investing in the development and production of monoclonal antibodies in Jiangsu, China, and is responsible for the marketing of its monoclonal antibody products.2024-06-03
more
-
Pharmaceutical Machinery and Equipment
Pharmaceutical machinery and equipment is an integral part of the pharmaceutical industry, covering all aspects from raw material processing to finished product packaging. We can conduct a detailed analysis of the market size, development trend and technological progress of China's pharmaceutical machinery and equipment industry.2024-05-30
more
-
Mobile Inspection Vehicle
A mobile inspection vehicle is a vehicle that integrates a variety of high-tech equipment and technologies for a variety of inspection tasks. These vehicles can be divided into several categories, each with its own specific application scenarios and functions.2024-05-25
more
-
Pekinpharma initiates first major collaboration to transfer its Adalimumab biosimilar turnkey solution
Pekinpharma's collaboration with ATM Medical Group in Indonesia, which enables the local production of biosimilar drugs through knowledge and capacity transfer, signals the potential of Pekinpharma's complete suite of solutions in providing affordable local biosimilar production. The collaboration will help enable a portfolio of biosimilar drugs developed by Pekinpharma, including monoclonal antibodies such as Adalimumab, to serve local manufacturers seeking to deliver essential medicines.2024-05-25
more
We are happy to help!
Discuss your questions or inquiries with our experts today.
Our other services
Pekin Pharma provides a wide range of science-driven and tailor-made solutions for many research, development, and analytical challenges. Explore all our services and learn how Coriolis can support your drug development program. Together, we can make future therapies available to patients and improve the quality of life for humankind.
Turnkey Project for Biosimilar manufacturing
Pekin Pharma provides complete design, engineering, construction, start-up of new pharmaceutical facilities, even assisting the Clients through scouting activities of potential Know How Licensor, transferring the Know How, providing Validation Master Plans and Standard Operating Procedures, validating, aligning industrial processes to URS and regulatory requirements.
The necessary training for operation and maintenance of the lines is provided by our expert technicians at the system start-up, ensuring a full understanding of how the equipment works and how to operate for effective sanitization/sterilization and troubleshooting. Different training for different access levels to the system is taken into account and recorded on the group certificate of attendance. Action options and limitations for the End-User, which are diversified according to the access level, are clearly highlighted during training.
Products Access:
No. |
Product Name |
Target |
CAS No. |
1 |
Pembrolizumab |
PD-1 |
1374853-91-4 |
2 |
Adalimumab |
TNF-α |
331731-18-1 |
3 |
Trastuzumab |
HER2 |
180288-69-1 |
4 |
Pertuzumab |
HER2 |
380610-27-5 |
5 |
Infliximab |
TNF-α |
170277-31-3 |
6 |
Bevacizumab |
VEGFR |
216974-75-3 |
7 |
Rituximab |
CD20 |
174722-31-7 |
8 |
Denosumab |
RANKL |
615258-40-7 |
9 |
Secukinumab |
IL-17 |
1229022-83-6 |
10 |
Tocilizumab |
IL-6R |
375823-41-9 |
11 |
Natalizumab |
Integrin α4 |
189261-10-7 |
12 |
Alemtuzumab |
CD52 |
216503-57-0 |
Contact
PEKIN PHARMA GROUP LTD.
Tel: +852 62336759
E-mail: info@pekin-pg.com
Address:H020 3/F PHASE 2 KWAI SHING IND BLD. 42-46 TAI LIN PAI RD. KWAI CHUNG NT, HONG KONG, CHINA.
Message